Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
NRZ - Q4 Core Earnings of $120 million, or $0.52 per diluted share*
GAAP Net Income of $103 million, or $0.45 per diluted share
Common dividend of $106 million, or $0.46 per share
FULL YEAR 2015 FINANCIAL HIGHLIGHTS:
Core Earnings of $389 million, or $1.92 per diluted share*
GAAP Net Income of $269 million, or $1.32 per diluted share
Common dividend of $355 million, or $1.75 per share
Increased quarterly common dividend in Q2 2015 and Q3 2015
http://finance.yahoo.com/news/residential-announces-fourth-quarter-full-115600160.html
SVT - i accumulated in the low 7's as this one
should have an easy comp and post strong results
in Q4 2015 vs a loss in Q4 2014.
They had EPS of .27 in Q2 and .33 in Q3.
"We are very pleased with the results for the first three quarters of the year," commented Kenneth Trbovich, President of Servotronics. "Our multi-year investment plan at the CPG is nearing completion and we are now manufacturing in the newly constructed facility. We have made substantial improvements to our operating efficiencies and will continue to focus on our programs of continuous improvement at both the ATG and CPG. We believe that these investments in the Company today will help us build the foundation that will be necessary for us to achieve our long-term goals for growth in sales and profitability."
http://finance.yahoo.com/news/servotronics-inc-announces-results-three-145000956.html
ESCC - bought back @.85 as someone
put a few blocks of 10-15k shares for sale
a few days ago.
6 months has passed since i sold (#msg-116760661),
they had great Q3 with EPS of .08. Backlog as of end of Q3,
was still strong @$29.2 million and yet the stock
trades lower than i sold it for.
The current price doesn't make sense.
They are a much stronger company after the pension
settlement on April 2015 (removing around $40M in pension liabilities in
exchange for payments totaling $10.5M over twelve years).
They also have an easy comp for Q4. They had a loss of .05 in
Q4 2014 and will probably post good results for Q4 2015.
ESCC - bought back @.85 as someone
put a few blocks of 10-15k shares for sale
a few days ago.
6 months has passed since i sold, they had great
Q3 with EPS of .08. Backlog as of end of Q3,
was still strong @$29.2 million and yet the stock
trades lower than i sold it for.
The current price doesn't make sense.
They are a much stronger company after the pension
settlement on April 2015 (removing around $40M in pension liabilities in exchange for payments totaling $10.5M
over twelve years).
They also have an easy comp for Q4. They had a loss of .05 in
Q4 2014 and will probably post good results for Q4 2015.
SVT - i accumulated in the low 7's as this one
should have an easy comp and post strong results
in Q4 2015 vs a loss in Q4 2014.
They had EPS of .27 in Q2 and .33 in Q3.
"We are very pleased with the results for the first three quarters of the year," commented Kenneth Trbovich, President of Servotronics. "Our multi-year investment plan at the CPG is nearing completion and we are now manufacturing in the newly constructed facility. We have made substantial improvements to our operating efficiencies and will continue to focus on our programs of continuous improvement at both the ATG and CPG. We believe that these investments in the Company today will help us build the foundation that will be necessary for us to achieve our long-term goals for growth in sales and profitability."
http://finance.yahoo.com/news/servotronics-inc-announces-results-three-145000956.html
MEET - The stock broke above the 50 day MA
@3.21 on big volume which is bullish and still
have room to go, but i did sell some as this is
a quick 27% profit from 2.7 where i bought after
your post. Another great call SSK. Thanks!
Excellent call SSK! Congrats.
EVOL - North African Operator Selects Evolving Systems' Dynamic SIM Allocation(TM) Solution
Overcoming Regulator Restrictions and Improving Number Utilization
Marketwired Evolving Systems
ENGLEWOOD, CO--(Marketwired - Feb 9, 2016) - Evolving Systems, Inc. (NASDAQ: EVOL), a leader in real-time activation, analytics and marketing for connected mobile devices, today announced that a prominent North African wireless operator has selected Evolving Systems' Dynamic SIM Allocation™ (DSA) solution to overcome regulatory constraints and improve number utilization. The project will be delivered in conjunction with a leading communications technology equipment, software and services vendor and is the first major engagement with this partner.
Relieving regulatory constraints and improving number utilization will help this operator grow its subscriber base and market share, which has a direct and positive impact on revenue. The DSA solution accomplishes this by effectively managing the operator's MSISDNs (or phone numbers) and ensuring MSISDNs are used only for an actual customer at the time of activation.
Wireless operators need to effectively manage their MSISDNs to meet demand, while also meeting the requirements of their local numbering authority. It is common for regulatory bodies to impose strict requirements on existing number utilization before they release additional numbers. Wireless operators often have to demonstrate that at least a minimum percentage of their allocated numbers are in use by active subscribers before being granted new number ranges.
With most pre-provisioning models, every prepaid SIM card in the distribution channel has a MSISDN pre-allocated to it, even if it's not being used by an active subscriber. For most emerging markets, with operators having rapidly growing subscriber bases, this often results in a very large number of MSISDNs that need to be allocated. The addition of lost or damaged SIM cards only complicates the problem.
"High subscriber growth coupled with churn often makes it difficult for a wireless operator to balance market demand with meeting regulatory requirements for MSISDN utilization," said Thomas Thekkethala, President and CEO at Evolving Systems. "With DSA, MSISDNs are not allocated to SIM cards until they are activated by a subscriber. This means that SIM cards in the distribution channel do not tie up MSISDNs, and a lost or damaged SIM card does not represent a wasted number. DSA is the answer to many regulator problems and will make it much easier for this operator to meet market demand, maintain and grow its subscriber base, and grow revenue."
About Evolving Systems®
Evolving Systems, Inc. (NASDAQ: EVOL) is a provider of software and services to 75 network operators in over 50 countries worldwide. The Company's portfolio includes market-leading subscriber service, SIM card and mobile broadband activation of connected devices and real-time analytics and marketing solutions to monetize mobile network services and consumer behavior. Founded in 1985, the Company has headquarters in Englewood, Colorado, with offices in the United States, United Kingdom, India, Malaysia and Romania. For more information please visit www.evolving.com or follow us on Twitter http://twitter.com/EvolvingSystems
EVOL - Sixth African Operator Selects Evolving Systems'
Dynamic SIM Allocation(TM) Solution
Extending the Number of Operators in a Major Wireless Multinational Group to Seven
Marketwired Evolving Systems
ENGLEWOOD, CO--(Marketwired - Jan 26, 2016) - Evolving Systems, Inc. (NASDAQ: EVOL), a leader in real-time activation, analytics and marketing for connected mobile devices, today announced that another wireless operator in Africa has selected the Company's Dynamic SIM Allocation™ (DSA) solution. The operator is part of a major multinational telecom group, and this is Evolving Systems' seventh order within the group.
Due to the unique way DSA activates subscribers -- by allocating phone numbers and network resources when the wireless device is purchased and used for the first time -- operators are able to streamline their SIM logistics and keep costs under control. These benefits, considered critical in emerging markets like Africa, allow operators to avoid SIM supply chain complexities and costs usually associated with pre-provisioning.
"We're very pleased to announce that a sixth operator in Africa, and the seventh from this leading telecom group, has selected our DSA solution for SIM activation," said Thomas Thekkethala, President and CEO of Evolving Systems. "DSA will help streamline the operator's SIM supply chain, increasing utilization while reducing operational costs. In addition, DSA will provide a highly personalized activation experience by allowing the subscriber a choice of number and tariff plan all via the handset. Our DSA solution is well on its way to becoming the standard SIM activation platform for the entire group."
Click here for more information on our DSA solution.
About Evolving Systems®
Evolving Systems, Inc. (NASDAQ: EVOL) is a provider of software and services to 75 network operators in over 50 countries worldwide. The Company's portfolio includes market-leading subscriber service, SIM card and mobile broadband activation of connected devices and real-time analytics and marketing solutions to monetize mobile network services and consumer behavior. Founded in 1985, the Company has headquarters in Englewood, Colorado, with offices in the United States, United Kingdom, India, Malaysia and Romania. For more information please visit www.evolving.com or follow us on Twitter http://twitter.com/EvolvingSystems
EVOL - Evolving Systems Announces Leadership Transition
Thomas Thekkethala Named Chief Executive Officer, Succeeding Thad Dupper, Who Will Remain With the Company as Chairman of the Board; Dan Moorhead Promoted to Chief Financial Officer
Marketwired Evolving Systems
ENGLEWOOD, CO--(Marketwired - Jan 4, 2016) - Evolving Systems, Inc. (NASDAQ: EVOL), a leader in real-time activation, analytics and marketing for connected mobile devices, today announced that Thomas Thekkethala, President of the Company, has been promoted to Chief Executive Officer. He succeeds Thad Dupper, who will remain with the Company as non-executive Chairman of the Board. In addition, Dan Moorhead, formerly Vice President, Finance and Administration, has been promoted to Chief Financial Officer.
Thekkethala assumes the CEO position after being named President and a Director of Evolving Systems when RateIntegration, Inc., d/b/a/ Sixth Sense Media (SSM), was acquired by Evolving Systems on September 30, 2015. Thekkethala was a founding investor, Chairman and CEO of SSM, a provider of real-time analytics and mobile marketing solutions to wireless carriers around the world, including tier 1 operators in India, Asia, Africa and Europe.
Thad Dupper, Chairman, said, "The acquisition of Sixth Sense Media accelerated Evolving Systems' entry into the rapidly expanding mobile marketing space -- an area that we expect to be an increasingly important contributor to our revenue growth in coming years. Thomas' expertise in mobile marketing -- in addition to his track record of leading technology growth companies -- makes him the right person to take Evolving Systems to the next level."
Prior to founding SSM, Thekkethala was founder and Managing General Partner of JT Ventures, a technology venture fund where he led investments in Allegro (acquired by Cisco), Fidelia (acquired by NetScout) and Ibrix (acquired by HP). Thekkethala also co-founded and led telecom software companies SRG Inc. and Consolidated Communications Systems and Services to successful acquisitions.
"We are grateful to Thad for his exceptional stewardship of the Company as CEO since 2007 and we are appreciative of his continued commitment to the business as the leader of our Board of Directors," said Julian Singer, a member of the Company's Board of Directors. "We look forward to working with Thomas as the Company's CEO. He is an exceptional leader and technologist, passionate about our mission, with a proven track record of building successful businesses."
Thekkethala commented, "On behalf of the entire Evolving Systems team, I'd like to thank Thad for his service and commitment to the Company over the years and look forward to his continued leadership of the Board. Mobile carriers have invested significantly in spectrum, network and customer acquisition but have not been able to participate in the rapidly expanding mobile marketing opportunity. I am extremely excited to take on this new role, working with the Evolving Systems leadership team to enable our mobile carrier customer base to generate new revenues across a range of mobile marketing channels."
The Board of Directors also promoted Dan Moorhead to serve as Chief Financial Officer. Mr. Moorhead is a certified public accountant and has been a member of the Company's finance team for approximately 11 years. Previously Mr. Moorhead held various management positions at High Country Club, Convergent Communications and the public accounting firm of Malouff and Co. "Over his long tenure with the Company, Dan has been a key member of the leadership team, managing finance and global operations, M&A and business development," said David Nicol, Chairman of the Audit Committee. "The Board is pleased to promote him to CFO, working closely with Thomas to grow the business and add shareholder value."
About Evolving Systems®
Evolving Systems, Inc. (NASDAQ: EVOL) is a provider of software and services to 75 network operators in over 50 countries worldwide. The Company's portfolio includes market-leading subscriber service, SIM card and mobile broadband activation of connected devices and real time analytics and marketing solutions to monetize mobile network services and consumer behavior. Founded in 1985, the Company has headquarters in Englewood, Colorado, with offices in the United States, United Kingdom, India, Malaysia and Romania. For more information on the Company, please visit www.evolving.com or follow us on Twitter http://twitter.com/EvolvingSystems
http://finance.yahoo.com/news/evolving-systems-announces-leadership-transition-120000425.html
AmpliTech Group Receives over $1 Million in Orders in 4th Quarter of 2015
BOHEMIA, NY / ACCESSWIRE / December 30, 2015 / AmpliTech Group, Inc. (AMPG) announced today that they have received over $1 million in orders in the 4th Quarter of 2015. The company also announced that they have reached a record high in revenues for 2015 which amounts to a 16% increase over last year's revenue.
CEO Fawad Maqbool commented, "Our strategy for increasing revenue and profitability is working and with the very large increase in bookings this year, we expect to have a great 2016 as well. With new products coming out next year and continued sales and marketing strategy, our revenue will continue to increase. Also, with new lower rate financing, we can improve our throughput as well as our bottom line. We are also proud to announce that we will be moving into a new larger facility with double the space we currently have. This will improve our production and increase the overall efficiency of our manufacturing and development process."
The Company plans to move into the new facility by February 1st, 2016.
About AmpliTech Group, Inc.
AmpliTech Group, Inc. designs, develops, and manufactures custom and standard state-of-the-art RF components for the Domestic and International, SATCOM, Space, and Military markets. These designs cover the frequency range from 50 kHz to 40 GHz - eventually, offering designs up to 100 GHz. AmpliTech also provides consulting services to help with any microwave components or systems design problems. Our steady growth over the past 13+ years has come about because we can provide complex, custom solutions for nearly ANY custom requirements that are presented us. In addition, we have the best assemblers, wires, and technicians in the industry and can provide contract assembly of customers' own designs. Click here to view AmpliTech video. Website: http://www.AmpliTechinc.com
hweb, Re CSPI & EVOL.
I bought CSPI after you posted about it @5.48
and sold today around 6.6 for 20% profit. Thank you!
In the last few days i have been buying EVOL.
Today i added 2000 @5.57.
I waited for stochastics (chart) to go down before
i started buying. Seems like the stock is consolidating
around this level and i like the big insider buys.
MOC - Thanks nelson & hweb.
MOC - sold @2.6-2.74 for over
50% profit. I am glad that i kept buying
it all the way from 1.6 to 1.85 a few days ago.
Also happy that the end of November deadline was met.
Thanks KIK.
LLTP up another 30% today. Sold some @10.85
for a 70% profit.
LLTP up another 30% today. Sold some @10.85
for a 70% profit.
LLTP FDA Approval news out: NARCAN(R) (Naloxone Hydrochloride) Nasal Spray Approved by U.S. Food and Drug Administration
Lightlake Therapeutics Inc.
40 minutes ago
GlobeNewswire
NEW YORK, Nov. 19, 2015 (GLOBE NEWSWIRE) -- Lightlake Therapeutics Inc. ("Lightlake") (LLTP), a specialty pharmaceutical company developing pharmacological treatments for substance use, addictive, and eating disorders announced today that the U.S. Food and Drug Administration (FDA) has approved NARCAN(R) (naloxone hydrochloride) Nasal Spray for the emergency treatment of known or suspected opioid overdose, to be marketed by Adapt Pharma Limited ("Adapt"), Lightlake's partner.
For more than 40 years naloxone has been trusted by healthcare providers for reversing the effects of opioid overdose, but until yesterday it was FDA approved only as an injection. NARCAN(R) Nasal Spray, to be marketed by Adapt, can be administered in an emergency by family members, caregivers, or others to reverse the effects of opioid overdose until help arrives. An opioid overdose may cause brain damage or death, so NARCAN(R) Nasal Spray should be administered as quickly as possible if a patient is unresponsive and an opioid overdose is suspected, even when in doubt. In the United States, opioid overdose related deaths are growing and claimed almost 24,500 lives in 2013, or an average of one life every 21 minutes.1 The majority of those deaths involved prescription opioids2 and happened in people's homes.3
In response, momentum to increase access to naloxone is building. In October, President Obama, included a call to make naloxone more readily available as part of a major initiative to address the nation's opioid epidemic.4 Major medical groups, including the American Medical Association and American Academy of Family Physicians, have also called for increased access to naloxone.5
"This is a very important day for physicians, patients, first responders, and caregivers," commented Dr. Roger Crystal, M.D., CEO of Lightlake. "This product has the potential to save thousands of lives each year. It has been a privilege to develop this drug in partnership with NIDA, and we're very pleased that our partner Adapt will be launching NARCAN(R) Nasal Spray very soon."
Lightlake plans to now focus on developing products for substance abuse, addictions, and eating disorders. Over the next year, Lightlake plans to bring the next generation of products into clinical trials.
In December 2014, Lightlake announced a licensing deal with a subsidiary of Adapt. As per the terms of the deal, in exchange for licensing its opioid overdose reversal treatment, Lightlake could receive potential development and sales milestone payments of more than $55 million, plus up to double-digit royalties.
Relevant Links
The National Institute on Drug Abuse (NIDA): http://www.drugabuse.gov/news-events/news-releases/2015/11/fda-approves-naloxone-nasal-spray-to-reverse-opioid-overdose
Adapt Pharma Limited: http://www.adaptpharma.com/press-releases/
Indications and Important Safety Information: http://www.NarcanNasalSpray.com
About Lightlake Therapeutics Inc.
Lightlake Therapeutics Inc. is a specialty pharmaceutical company developing pharmacological treatments for substance use, addictive, and eating disorders. Lightlake has entered into a licensing deal with a subsidiary of Adapt Pharma Limited with respect to a treatment to reverse opioid overdoses, which have reached epidemic proportions in the United States. Lightlake also has collaborated on clinical trials with the National Institute on Drug Abuse, part of the National Institutes of Health, with respect to this treatment. In addition, Lightlake has completed a Phase II clinical trial to treat Binge Eating Disorder. For more information please visit: www.lightlaketherapeutics.com.
https://finance.yahoo.com/news/narcan-r-naloxone-hydrochloride-nasal-133000479.html
LLTP FDA Approval news out: NARCAN(R) (Naloxone Hydrochloride) Nasal Spray Approved by U.S. Food and Drug Administration
Lightlake Therapeutics Inc.
40 minutes ago
GlobeNewswire
NEW YORK, Nov. 19, 2015 (GLOBE NEWSWIRE) -- Lightlake Therapeutics Inc. ("Lightlake") (LLTP), a specialty pharmaceutical company developing pharmacological treatments for substance use, addictive, and eating disorders announced today that the U.S. Food and Drug Administration (FDA) has approved NARCAN(R) (naloxone hydrochloride) Nasal Spray for the emergency treatment of known or suspected opioid overdose, to be marketed by Adapt Pharma Limited ("Adapt"), Lightlake's partner.
For more than 40 years naloxone has been trusted by healthcare providers for reversing the effects of opioid overdose, but until yesterday it was FDA approved only as an injection. NARCAN(R) Nasal Spray, to be marketed by Adapt, can be administered in an emergency by family members, caregivers, or others to reverse the effects of opioid overdose until help arrives. An opioid overdose may cause brain damage or death, so NARCAN(R) Nasal Spray should be administered as quickly as possible if a patient is unresponsive and an opioid overdose is suspected, even when in doubt. In the United States, opioid overdose related deaths are growing and claimed almost 24,500 lives in 2013, or an average of one life every 21 minutes.1 The majority of those deaths involved prescription opioids2 and happened in people's homes.3
In response, momentum to increase access to naloxone is building. In October, President Obama, included a call to make naloxone more readily available as part of a major initiative to address the nation's opioid epidemic.4 Major medical groups, including the American Medical Association and American Academy of Family Physicians, have also called for increased access to naloxone.5
"This is a very important day for physicians, patients, first responders, and caregivers," commented Dr. Roger Crystal, M.D., CEO of Lightlake. "This product has the potential to save thousands of lives each year. It has been a privilege to develop this drug in partnership with NIDA, and we're very pleased that our partner Adapt will be launching NARCAN(R) Nasal Spray very soon."
Lightlake plans to now focus on developing products for substance abuse, addictions, and eating disorders. Over the next year, Lightlake plans to bring the next generation of products into clinical trials.
In December 2014, Lightlake announced a licensing deal with a subsidiary of Adapt. As per the terms of the deal, in exchange for licensing its opioid overdose reversal treatment, Lightlake could receive potential development and sales milestone payments of more than $55 million, plus up to double-digit royalties.
Relevant Links
The National Institute on Drug Abuse (NIDA): http://www.drugabuse.gov/news-events/news-releases/2015/11/fda-approves-naloxone-nasal-spray-to-reverse-opioid-overdose
Adapt Pharma Limited: http://www.adaptpharma.com/press-releases/
Indications and Important Safety Information: http://www.NarcanNasalSpray.com
About Lightlake Therapeutics Inc.
Lightlake Therapeutics Inc. is a specialty pharmaceutical company developing pharmacological treatments for substance use, addictive, and eating disorders. Lightlake has entered into a licensing deal with a subsidiary of Adapt Pharma Limited with respect to a treatment to reverse opioid overdoses, which have reached epidemic proportions in the United States. Lightlake also has collaborated on clinical trials with the National Institute on Drug Abuse, part of the National Institutes of Health, with respect to this treatment. In addition, Lightlake has completed a Phase II clinical trial to treat Binge Eating Disorder. For more information please visit: www.lightlaketherapeutics.com.
https://finance.yahoo.com/news/narcan-r-naloxone-hydrochloride-nasal-133000479.html
LLTP (6.27) - Got FDA approval only 2 months after
the PR about FDA accepting for Review their
NARCAN Nasal Spray and 2 months before the PDUFA date.
This is rare.
LLTP's market cap is tiny and they have
only 1.87 million OS shares.
There is no PR from the company yet, but there
is one on their partner's site, Adapt pharma.
http://www.adaptpharma.com/press-releases/
Dublin, Ireland – November 18, 2015 – Adapt Pharma Limited (www.adaptpharma.com) announced today that the U.S. Food and Drug Administration (FDA) has approved NARCAN® (naloxone hydrochloride) Nasal Spray for the emergency treatment of known or suspected opioid overdose.
For more than 40 years, naloxone has been trusted by healthcare providers for reversing the effects of opioid overdose, but until today, it was FDA approved only as an injection.
NARCAN Nasal Spray, a ready-to-use, needle-free device, delivers a 4 mg dose of naloxone in a single 0.1 ml nasal spray. NARCAN Nasal Spray requires no assembly or priming prior to use. Adapt Pharma is committed to affordable and transparent pricing of NARCAN Nasal Spray. Group purchasers, such as law enforcement, fire fighters, first responders, departments of health, local school districts, colleges and universities, and community-based organizations that order directly from Adapt Pharma, are eligible for a discounted Public Interest Price of $37.50 per 4mg NARCAN Nasal Spray device ($75 for a carton containing 2 devices of NARCAN Nasal Spray 4mg).1
We are delighted to have reached agreement with the Clinton Health Matters Initiative, an initiative of the Clinton Foundation, our first partner in establishing this discounted Public Interest Price approach. “The Clinton Health Matters Initiative is committed to efforts to reduce opioid overdose deaths, including by making naloxone more widely available," said Rain Henderson, CEO of the Clinton Health Matters Initiative, an initiative of the Clinton Foundation. "We believe that the partnership and pricing agreement with Adapt will assist us in helping organizations across the United States to save lives by making naloxone more affordable and accessible for those who need it most."
We expect to announce additional partnerships soon. To learn more, group purchasers may call 844-4-NARCAN (844-462-7226) or email customerservice@adaptpharma.com. For individuals with health insurance coverage, NARCAN Nasal Spray is expected to have broad coverage with affordable co-pays.
NARCAN Nasal Spray can be administered in an emergency by family members, caregivers or others to reverse the effects of opioid overdose until help arrives. An opioid overdose may cause brain damage or death, so NARCAN Nasal Spray should be administered as quickly as possible if a patient is unresponsive and an opioid overdose is suspected, even when in doubt.
In the United States, opioid overdose related deaths are growing and claimed almost 24,500 lives in 2013, or an average of one life every 21 minutes.2 The majority of those deaths involved prescription opioids3 and happened in people’s homes.4
In response, momentum to increase access to naloxone is building. In October, President Obama included a call to make naloxone more readily available as part of a major initiative to address the nation’s opioid epidemic.5 Major medical groups, including the American Medical Association and American Academy of Family Physicians, have also called for increased access to naloxone.6
“Opioid overdose is responsible for the deaths of thousands of Americans in communities throughout the country, leaving a trail of devastation for friends and families,” said Seamus Mulligan, Chairman and CEO of Adapt Pharma. “NARCAN Nasal Spray a ready-to-use, needle-free device, delivers a 4 mg dose of naloxone in a single 0.1 ml nasal spray. This new device makes naloxone readily available for emergency use by a friend, family member or caregiver, as well as offering an alternative treatment option for first responders and healthcare providers. It gives new hope to those concerned about the potentially fatal effects of opioid overdose.”
Anyone who uses prescription opioids for the long term management of chronic pain, or those who take heroin, are potentially at risk of experiencing a life-threatening or fatal opioid overdose where breathing and heart beat slow or stop.7 Prescription opioids include morphine, codeine, methadone, oxycodone (e.g. OxyContin®, Percocet®), hydrocodone (e.g. Vicodin®, Lortab®), fentanyl (e.g. Duragesic®, Fentora®), hydromorphone (e.g. Dilaudid®, Exalgo®), oxymorphone (Opana® ER), and buprenorphine (Subutex®, Suboxone®). Illicit opioids include heroin and increasingly heroin/fentanyl mixes.
“Overdoses can potentially occur anytime and anywhere opioids are being used. That is why expanding access to naloxone, which can rapidly reverse an overdose, is being encouraged by several professional organizations,” said Dr. Anita Gupta, a board-certified anesthesiologist, pharmacist and pain specialist. “By making naloxone available and easy to use for anyone taking an opioid, as well as their family members and loved ones, we may be able to decrease needless opioid overdose deaths.”
“After my son’s passing, I made a vow to him that I was going to save a life in his name,” said David Humes, who lost his 24-year-old son, Gregory, to an accidental heroin overdose in May 2012. “Since then, I have been a passionate advocate for the broader distribution and use of naloxone. I believe the approval of additional opioid overdose treatment options, like NARCAN Nasal Spray, may greatly increase access to this potentially lifesaving medication. Expanding access to naloxone became my path toward fulfilling my vow to my son and helping to prevent a similar heartbreak for other parents.” Adapt Pharma collaborated with the National Institutes on Drug Abuse (NIDA) on the development of NARCAN Nasal Spray, which received Fast Track Designation and a Priority Review by the FDA.
Adapt Pharma originally licensed the project from Lightlake Therapeutics, Inc. It is available in a carton containing two blister packages, each with a single NARCAN Nasal Spray containing a single 4 mg dose of naloxone hydrochloride intranasal spray.
ABOUT NARCAN NASAL SPRAY
NARCAN Nasal Spray is indicated for the emergency treatment of known or suspected opioid overdose, as manifested by respiratory and/or central nervous system depression.
NARCAN Nasal Spray is intended for immediate administration as emergency therapy in settings where opioids may be present.
NARCAN Nasal Spray is not a substitute for emergency medical care. Always seek emergency medical assistance in the event of a suspected, potentially life-threatening opioid emergency after administration of the first dose of NARCAN nasal spray.
If the desired response is not obtained after 2 or 3 minutes, administer an additional dose of NARCAN Nasal Spray using a new NARCAN Nasal Spray. If the patient responds to NARCAN Nasal Spray and relapses back into respiratory depression before emergency assistance arrives, administer an additional dose and continue surveillance of the patient. If there is still no response and additional doses are available, administer additional doses of NARCAN Nasal Spray every 2 to 3 minutes using a new NARCAN Nasal Spray with each dose until emergency medical assistance arrives. Additional supportive and/or resuscitative measures may be helpful while awaiting emergency medical assistance.
Please see Indications and Important Safety Information below. Full prescribing information for NARCAN Nasal Spray, including important safety information, is also available at www.NarcanNasalSpray.com.
AVAILABILITY OF NARCAN NASAL SPRAY
Once launched, in early 2016, we expect NARCAN Nasal Spray will be available at retail pharmacies.
MOC - bought more in the last few days
@1.85. In the earnings release a few days ago,
the CEO said "we remain confident that the U.S. Postal Service contract will be resolved positively in the near term.”
In the 10Q it says: "the Company, and the USPS expressed an intent to stay the transition of the USPS Contract awarded the Company pending resolution of the Court of Federal Claims protest filed by ABM. The Court of Federal Claims dismissed the protest filed by ABM on July 7, 2015 to allow for the USPS to take corrective action.
Many variables make it impossible to accurately predict the actual duration of the current protest proceedings. Although we are hopeful that a corrected award decision will be issued before the end of November, we cannot predict when such a decision will occur or when the protest proceeding will conclude. In addition, the Company cannot predict the outcome of the dispute, including whether the transition will occur."
Even if they don't get it by the end of November,
they will probably get it in the next few weeks after that.
LLTP (6.27) - Got FDA approval. There is no
PR from the company yet, but there
is one on their partner's site, Adapt pharma.
http://www.adaptpharma.com/press-releases/
Thanks for bringing it to this board 2 months
ago. I put it on my watch list and bought in
the last few days @6.3-6.6
With the tiny market cap, only 1.87 million OS shares
and surprise approval, it will be an interesting day.
LLTP (6.27) - this is another bio that i bought in
the last few days @6.3-6.6
LLTP's market cap is tiny and they have
only 1.87 million OS shares.
I bought it because two months ago, the FDA
accepted for Review their NARCAN Nasal Spray
NDA and Granted Priority Review Status.
http://finance.yahoo.com/news/lightlake-therapeutics-inc-announces-fda-123000038.html
On that PR the stock went to as high as $14,
so i was happy to buy it when it went back to below $7.
To my surprise, it seems like they got approval,
only 2 months after the PR about FDA
accepting for Review their NARCAN Nasal Spray
and 2 months before the PDUFA date. This is rare.
There is no PR from the company yet, but there
is one on their partner's site, Adapt pharma.
http://www.adaptpharma.com/press-releases/
With the tiny market cap, only 1.87 million OS shares
and surprise approval, it will be an interesting day.
KINS - Kingstone Insurance Approved to Write Property and Casualty Insurance in Connecticut
Business Wire Kingstone Companies, Inc.
KINGSTON, N.Y.--(BUSINESS WIRE)--
Kingstone Companies, Inc. (KINS) (the “Company” or “Kingstone”), a multi-line property and casualty insurance holding company, today announced that its subsidiary, Kingstone Insurance Company, was granted approval to write property and casualty insurance in Connecticut from the Connecticut Insurance Department.
In addition to New York, Pennsylvania, and Texas, Connecticut is the fourth state where the Company is authorized as an admitted carrier of property and casualty insurance.
Kingstone’s Chairman and CEO, Barry Goldstein, commented, “Our admission into Connecticut is another step in our geographic expansion plans, and we look forward to beginning to write competitive products in a neighboring state to our headquarters in New York. In the last two months, Kingstone has continued its multi-state expansion with the addition of Connecticut and Texas. We intend to leverage our “B++” (Good) A.M. Best rating coupled with our strong reputation in the New York independent producer community to build out an agency-only distribution network that will provide policyholders with the same high-level of service that Kingstone has been committed to for over 100 years.”
Kingstone expects to continue its expansion into other states. The Company currently has applications for admission pending in two additional states, each of which share similar catastrophe exposures and opportunities as New York.
http://finance.yahoo.com/news/kingstone-insurance-approved-write-property-130000818.html
MOC - still holding and even bought
more @1.8. I didn't buy it for a 10-15%
flip. I hope that in the next month or
two they will get a favorable ruling, get
the contract and the stock will move up
to $2.5 at least.
ESCC - sold the rest around .97 for
a 75% profit. The stock is up 36% with
big volume on another nasty market day.
SLGD - sold @1.35 for 40% profit.
MOC - i also wanted to get more in the
1.60's. I accumulated 13000 @1.6-1.65 but
wanted at least 25000.
This is a good price and approx 40%
lower than i sold it for in June #msg-114704024.
As i told you before, this shouldn't
take a year and after i read the 10Q, i decided that
it was time to start accumulating.
From the 10Q:
On June 17, 2015, the Company was notified by the United States Department of Justice that ABM has expressed intent to file a protest with the Court of Federal Claims challenging the award of the USPS contract to the Company, and seeking an injunction to stop the transition of the USPS contract to the Company. On June 23, 2015, ABM filed a protest with the Court of Federal Claims challenging the award of the USPS contract to the Company, and the USPS expressed an intent to stay the transition of the contract awarded the Company pending resolution of the Court of Federal Claims protest filed by ABM.
Many variables make it impossible to accurately predict the actual duration of the current protest proceedings. Although we are hopeful that the protest proceedings will conclude before the end of September, we cannot predict when the protest proceeding will conclude or how long thereafter it may take the federal judge hearing the case to issue a ruling. In addition, the Company cannot predict the outcome of the dispute, including whether the transition will occur.
Of course it's wrong. The Dow was
around 450 in 1929 and below 50! after the crash:
http://stockcharts.com/freecharts/historical/marketindexes.html
AmpliTech Group Reports Second Quarter Profit
PR Newswire AmpliTech Group, Inc.
NEW YORK, Aug. 18, 2015 /PRNewswire/ -- AmpliTech Group, Inc. (AMPG) filed their 10-Q for the second quarter of 2015. CEO Fawad Maqbool stated, "AmpliTech Group is proud to announce that it has maintained its profitability into the second quarter of 2015. We have been working on expanding product lines and increasing our business revenues by joint venturing with other OEMs in this technology space. We have entered into re-selling and private labeling agreements with other companies that offer increased marketing and distribution channels which gives us two key benefits: 1) increased sales, and 2) expanded new product lines to address a broader base of customers. In addition to that, we are continuing our efforts to develop new products with our internal R&D, in the wireless infrastructure arena which will lead to more sales and profitability in the near future. Our profit has remained consistent since we chose to put much of it into R&D, hiring engineering personnel, and expanding our marketing efforts with a successful trade show in Phoenix. We have also increased online and print advertising which we believe will lead to more revenue as well." Below are some key highlights for the first half of 2015:
Revenue for first half of 2015 (ending 6/30/2015) increased by 13% compared to same period last year
Corresponding increase in gross profit of 23% compared to same period last year
Interest expense down from last year by 84% or $106,759 due to elimination of debt
EBITDA of $129,302 for AmpliTech, Inc, the wholly owned subsidiary of AMPG
Consolidated EBITDA of $74,330 for AMPG
Book to Bill Ratio of 1.2
Reduction of liabilities by approximately $60,000 from 12/31/2014
Mr. Maqbool added, "We are still in the process of evaluating the most favorable investment options from private investors and funds to boost our growth rate and overall valuation."
About AmpliTech Group, Inc.
AmpliTech Group, Inc. designs, develops, and manufactures custom and standard state-of-the-art RF components for the Domestic and International, SATCOM, Space, and Military markets. These designs cover the frequency range from 50 kHz to 40 GHz - eventually, offering designs up to 100 GHz. AmpliTech also provides consulting services to help with any microwave components or systems design problems. Our steady growth over the past 13+ years has come about because we can provide complex, custom solutions for nearly ANY custom requirements that are presented us. In addition, we have the best assemblers, wires, and technicians in the industry and can provide contract assembly of customers' own designs. Click here to view AmpliTech video. Website: http://www.AmpliTechinc.com
http://finance.yahoo.com/news/amplitech-group-reports-second-quarter-120000072.html
Yes, it is! Between ESCC & SLGD it is
a beautiful day.
ESCC - sold most @.87-.92 for over
60% profit. Not bad for a month holding.
ESCC - up 30% to .89. Evans & Sutherland Reports Second Quarter 2015 Results
http://finance.yahoo.com/news/evans-sutherland-reports-second-quarter-160600493.html
SLGD, Yes, great results! I am reading the
10Q now.
http://ih.advfn.com/p.php?pid=nmona&article=68179898&symbol=SLGD
Another profitable Q and increased revenues.
Earned 10k vs a loss of 556k in Q2 2014 and
revenues are up 19% to 379k from 320k in Q2 2014.
http://www.sec.gov/Archives/edgar/data/1518461/000147793215005123/ampg_10q.htm
Yes. IPCI's Rexista™ Oxycodone XR product candidate has been further enhanced with its proprietary PODRAS™ delivery technology intended to reduce the likelihood of oral abuse when more pills than prescribed are swallowed intact. Preclinical studies of Rexista™ Oxycodone XR suggest that if more tablets than prescribed are deliberately or inadvertently swallowed, the amount of drug active released over 24 hours may be substantially less than expected. However, if the prescribed number of pills is swallowed, the drug release should be as expected.
PFIN - sold the rest around 9.9 for
a 54% profit. Great Q2 results and the
stock hitting new 52wk high.
Thanks stocking4ms. So nothing special here
with the other ANDA's. This also took more
than 6 years for the pathetic FDA to approve.